Neovasc stock (NVCN) is surging: what’s next?

5:26 am ET, 07 Aug 2018

Neovasc Inc. (NVCN) shares are trading at 0.05, up 14%.  This is a significant price movement for the stock, and speculators are excited there is more good news to come.  What's driving NVCN stock price? What's NVCN stock price forecast?

Just yesterday Neovasc resolved potential legal claims that could be brought against the company with the University of Pennsylvania (a.k.a. Penn).  The firm has signed a collaboration and licensing agreement with Penn's Gorman Cardiovascular Research Group. Based on the agreement, for a period of time over the next four years Neovasc will pay a fee to Penn. The company will also pay a royalty on Tiara, its cornerstone product, to Penn.  This agreement does not impact either Penn's or Neovasc's patent rights, and it also contains buyout clauses which allow a potential acquirer to buy out the royalty obligations.

This is significant news for the company that received a delisting notification from Nasdaq.  Regarding delisting, Neovasc will request a hearing before the Nasdaq Hearings Panel as the next step, seeking an additional 180-day extension for compliance with the $1 minimum bid price requirement.  

Our technical analysis shows that: 

  • The stock short-term sentiment (next 30 days) is negative;
  • The mid-term sentiment (3-6 months) is trending positive;
  • The long-term sentiment (9-12 months) is negative.

Over the last month, Neovasc Inc. (NVCN) returned -20.19%.

Neovasc Inc. (NVCN) short share of float is 5.61%. The stock is much more frequently shorted than the average industry, sector or S&P 500 stock.

Neovasc Inc. (NVCN) average analyst price target ($0.99), significantly above its current price.

For the latest price and information on Neovasc Inc., please visit Finstead and search for "NVCN price" or "NVCN news".

Neovasc (NVCN): Time To Gamble?

1:45 pm ET, 13 Apr 2018

Neovasc (NASDAQ: NVCN) stock is down 6% in mid-day trading.  It fell 90% during the last 3 month.

However, the investor optimism is at an all-time high. On Stocktwits, the investor sentiment is 97% positive, and the volume of messages reached a record of 33,000.

On 4th April, the shares hit a twelve-month low (3 cents per share).  Neovasc has 0% trailing twelve-month Return on Assets, which is a clear indication of the company's lack of profitability.

Investors were excited when Neovasc declared it will exercise 4,885,266 Series C Warrants yesterday.  This results in a $7,132,488 investment (a part of the underwritten public offering from November 2017).

The much-needed capital will extend Neovasc’s runway for an additional 4 months. The company's current cash is now 60% higher.

The stock is an ideal target for penny flippers. Will it bounce back? 

Per Finstead Research, Neovasc shares have the average price target of almost $4.

The four analysts rating the stock give it a strong buy. 

One thing is sure—if you buy this stock, be prepared for a wild ride.  You can easily lose all of your wealth, or double it!  

Neovasc (NVCN): Will The Stock Price Rise Soon?

7:17 pm ET, 27 Mar 2018

Neovasc (NASDAQ: NVCN), a medical device company, witnessed a dip in its stock price over the last 7 days.

Neovasc develops and markets cardiovascular products.

In a written notification from NASDAQ, Neovasc was informed about its non-compliance with the maintenance of minimum $35 Million market value standard. 

There has been no improvement in its market value for 30 continuous business days from February 6, 2018, to March 21, 2018, which led NASDAQ to take the step. The notification doesn't imply Neovasc’s delisting from the Nasdaq Capital Market.

If the company doesn’t do anything about this until September 18, 2018, to ensure its compliance with the standard, NASDAQ will take an action.  Neovasc’s market value should be more than the US $35 million for 10 continuous business days by the specified deadline.

There won't be any impact on the company's operations or its compliance status on the Toronto Stock Exchange.

There is a lot of fear about Neovasc’s future, which is the reason why the shares trade so low.  

Should this be the case?

Per Finstead research, Neovasc’s average price target is almost $4 which is far away from its current price ($0.11). Its upside is over 3,000%.

Neovasc’s valuation ratios (e.g., forward P/E ratio) are all negative.  This is an indication that the company is unprofitable.  So trading its shares is highly speculative and not recommended unless you're a market expert.

Neovasc Inc. (NVCN) Stock Guide

Updated at: 12:37 am ET, 22 Sep 2020

Before we start: if you're looking for NVCN stock price, you can quickly find it out by visiting Finny and typing "NVCN quote". If you're looking for a quick scoop on NVCN stock (chart, price target, market cap, news and buy or sell analysis), go to Finny and look for "NVCN". You'll get all this info in one place. Or you can just type "NVCN news" to get the latest stock news.

Looking to buy or sell Neovasc Inc. (NVCN)? Interested in getting the full scoop on NVCN, including earnings and dividends, stock forecast, buy or sell analysis and key stats? If so, you came to the right place.

In this NVCN stock guide, we'll address key questions about NVCN, above and beyond what you can find on Yahoo Finance, Zacks, MarketWatch or Morningstar.

Here is what you'll be able to find in this guide:

Earnings and Dividends: earnings, earnings date, dividend rate and dividend yield;
Analyst Predictions: stock forecast and analyst ratings;
Analysis: Finny Score and buy or sell analysis;
Key Stats: revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio, industry, sector, and number of employees.

And here is the list of questions we'll answer:
1. What are NVCN earnings?
2. When is NVCN earnings date?
3. What is NVCN stock forecast (i.e., prediction)?
4. NVCN buy or sell? What is NVCN Finny Score?
5. What are the reasons to buy NVCN? Why should I buy NVCN stock?
6. What are the reasons to sell NVCN? Why should I sell NVCN stock?
7. What are NVCN key stats: revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio industry, sector, and number of employees?

So let's start. Scroll down to the question that interests you the most.

Earnings and Dividends

1. What are NVCN earnings?

NVCN trailing 12-month earnings per share (EPS) is -$3.40.

2. When is NVCN earnings date?

NVCN earnings date is undefined.

Analyst Predictions

3. What is NVCN stock forecast (i.e., prediction)?

Based on NVCN analyst price targets, NVCN stock forecast is $1.88 (for a year from now). That means the average analyst price target for NVCN stock is $1.88. The prediction is based on 1 analyst estimates.

The low price target for NVCN is $1.50, while the high price target is $2.25.

NVCN analyst rating is Strong Buy.


4. NVCN buy or sell? What is NVCN Finny Score?

#{finnyScore:43}Our quantitative analysis shows 3 reasons to buy and 4 reasons to sell NVCN, resulting in Finny Score of 43.

5. What are the reasons to buy NVCN? Why should I buy NVCN stock?

Here are the reasons to buy NVCN stock:

6. What are the reasons to sell NVCN? Why should I sell NVCN stock?

Let's look at the reasons to sell NVCN stock (i.e., the bear case):

Key Stats

7. What are NVCN key stats : revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio industry, sector, and number of employees?

Let's look at the key statistics for NVCN:

Metrics NVCN
Price $2.07
Average Price Target / Upside $1.88 / -9.18%
Average Analyst Rating Strong Buy
Forward Dividend Yield 0.00%
Industry Medical Devices
Sector Healthcare
Number of Employees 110
Market Cap $50.62M
Forward P/E Ratio -17.31
Price/Book Ratio 26.88
Revenue (TTM) $1.88M
YoY Quarterly Revenue Growth -35.40%
Profit Margin 0.00%

If you liked this analysis, check out Stock Guides for other stocks.

Follow Us